Showing 1771-1780 of 2123 results for "".
- One-Year Data from OCARINA II Show Suppression of Relapses/Lesions in MS with Subcutaneous Ocrevus Treatmenthttps://practicalneurology.com/news/one-year-data-from-ocarina-ii-show-suppression-of-relapseslesions-in-ms-with-subcutaneous-ocrevus-treatment/2470456/Data from the OCARINA II study (NCT05232825) presented at the American Academy of Neurology (AAN) 2024 Annual Meeting showed that subcutaneous (SC) injection of Ocrevus (ocrelizumab; Genentech, South San Francisco, CA) resulted in near-complete suppression of clinical relapses and brain lesions i
- Elfabrio Shows Comparable Efficacy to Agalsidase Beta at 2 Years as Treatment for Fabry Diseasehttps://practicalneurology.com/news/elfabrio-shows-comparable-efficacy-to-agalsidase-beta-at-2-years-as-treatment-for-fabry-disease/2470380/New results from the phase 3 BALANCE clinical trial (NCT02795676), published in the Journal of Medical Genetics, demonstrated that Elfabrio (pegunigalsidase alfa-iwxj; Chiesi Global Rare Diseases, Boston, MA; Portalix BioTherapeutics, Carmiel, Israel) was well-tolerated and has comparabl
- 81% of Infants with SMA Treated with Evrysdi for 1 Year Able to Sit Independently According to RAINBOWFISH Studyhttps://practicalneurology.com/news/81-of-infants-with-sma-treated-with-evrysdi-for-1-year-able-to-sit-independently-according-to-rainbowfish-study/2470318/According to an analysis of data from the RAINBOWFISH clinical trial (NCT03779334), treatment with Evrysdi (risdiplam; Genentech, South San Francisco, CA) in infants with presymptomatic spinal muscular atrophy (SMA) resulted in favorable outcomes. The new results were presented at the 28th World
- Stroke Risk Increases Significantly After Head Injury, 30-Year Study Findshttps://practicalneurology.com/news/stroke-risk-increases-significantly-after-head-injury-30-year-study-finds/2470292/People who have experienced traumatic brain injury (TBI), regardless of severity, are at significantly greater risk of ischemic stroke, according to a study presented at the 148th Annual Meeting of the American Neurological Association. The study also found that the risk of ischemic stroke increa
- Zavzpret Now Available in US Pharmacies as a Nasal Spray Treatment for Migrainehttps://practicalneurology.com/news/zavzpret-now-available-in-us-pharmacies-as-a-nasal-spray-treatment-for-migraine/2470250/Zavzpret (zavegepant; Pfizer, New York, NY), a nasal spray that treats migraine, is now available in US pharmacies as a package of 6 single-use, disposable devices that deliver a 10 mg dose. The
- CGRP mAbs Are Effective Long-Term for Migraine Prevention According to 3-Year Longitudinal Studyhttps://practicalneurology.com/news/cgrp-mabs-are-effective-long-term-for-migraine-prevention-according-to-3-year-longitudinal-study/2470218/Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) demonstrated long-term efficacy in preventing migraines, according to a study presented at the 65th Annual Scientific Meeting of the American Head
- Five-Year Data from ALITHIOS Study on MS Disability Presented at AAN 2023https://practicalneurology.com/news/five-year-data-from-alithios-study-on-ms-disability-presented-at-aan-2023/2470163/According to long-term results of a study presented at the Americ
- Combination Therapy May Reduce Weight Gain in Young Adults With Serious Mental Illnesshttps://practicalneurology.com/news/combination-therapy-may-reduce-weight-gain-in-young-adults-with-serious-mental-illness/2470145/Accord
- Open Label Extension Trial of Ozanimod Confirms Disease Stability at 6-7 Yearshttps://practicalneurology.com/news/open-label-extension-trial-of-ozanimod-confirms-disease-stability-at-6-7-years/2470126/Data from 2 phase 3 trials and one open label extension study (OLE) used to evaluate long-term efficacy by patient age group were presented at the Americas Committee for Treatment & Research in Multiple Sclerosis (ACTRI
- Brand-Name Epilepsy Drug Costs Increase Almost Threefold Over 8 Yearshttps://practicalneurology.com/news/brand-name-epilepsy-drug-costs-increase-almost-threefold-over-8-years/2469944/According study published in Neurology, there was threefold increase in the cost of brand-name antiseizure medications (ASMs) in from 2010 to 2018. Brand-name medications comprised 79% of ASM costs although they made up only 14% of ASMs used. “The costs for brand-name A